Stay updated with breaking news from Mapi Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis...
Health news and commentary from around the Web gathered by <em>MedPage Today</em> staff
The AI fever that took hold of investors in the past few months is showing some signs of easing. Investors are wondering if things are going a bit too fast, which led to some sell-offs in iconic... -March 11, 2024 at 09:38 am EDT - MarketScreener
GA Depot 40mg is a long-acting version
The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.